Pazopanib hydrochloride is primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. It works by inhibiting multiple tyrosine kinases, which are involved in tumor growth and angiogenesis. This helps to slow down or stop the progression of cancer by blocking the blood supply to tumors. In clinical practice, it is administered orally, offering a convenient treatment option for patients. It is often prescribed when other treatments have not been effective or are unsuitable. Patients undergoing this therapy are closely monitored for side effects, such as hypertension, liver dysfunction, and fatigue, to ensure safe and effective use. Additionally, pazopanib hydrochloride has shown potential in research for treating other types of cancers, though these applications are still under investigation. Its targeted mechanism of action makes it a valuable option in personalized cancer therapy.